Hajikarimloo B, Mohammadzadeh I, Tos SM, Hasanzade A, Sahrai H, Taghipour P, Amjadzadeh M, Najari D, Ebrahimi A, Roustaei E, Habibi MA. Stereotactic radiosurgery for tumor-related trigeminal neuralgia: a systematic review and meta-analysis.
BMC Neurol 2025;
25:195. [PMID:
40319265 PMCID:
PMC12048969 DOI:
10.1186/s12883-025-04204-6]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2025] [Accepted: 04/23/2025] [Indexed: 05/07/2025] Open
Abstract
BACKGROUND
Tumor-related trigeminal neuralgia (TRTN) accounts for approximately 6% of all facial pain syndromes. Conventional medical treatments have short-term pain relief effects in TRTN cases; however, they are correlated with substantial failure rates of 63-100%. Microsurgical resection (MS) and stereotactic radiosurgery (SRS) are the two primary therapeutic options for the management of TRTNs. This systematic review and meta-analysis evaluated the pain-related outcomes and complications of SRS in TRTNs.
METHODS
A systematic literature search was conducted on February 24, 2025, comparing PubMed, Embase, Scopus, and Web of Science. Studies reporting pain-related outcomes and adverse radiation effects (ARE) for SRS in TRTNs were included.
RESULTS
Nineteen studies with 454 patients were included. Meningioma (67.7%, 304/449) was the most common tumor, followed by vestibular schwannoma (VS) (18.3%, 82/449) and trigeminal schwannoma (8.2%, 37/449). Our meta-analysis demonstrated that SRS is associated with a pooled complete pain-free rate of 38% (95% CI: 27-50%), an adequate pain relief rate of 73% (95% CI: 63-83%), and an ARE rate of 14% (95% CI: 7-22%). In those where the underlying etiology was pertoclival meningiomas, SRS resulted in a pooled complete pain-free rate of 30% (95%CI: 5-64%), an adequate complete pain relief rate of 64% (95%CI: 33-90%), and an ARE rate of 13% (95%CI: 0-48%).
CONCLUSION
SRS is associated with favorable pain-related outcomes and low ARE rates in patients with TRTN. Both tumor-only related and dual-targeted approaches are associated with comparable outcomes.
Collapse